Yamaguchi, Kensei http://orcid.org/0000-0001-6887-5709
Fujitani, Kazumasa
Nagashima, Fumio
Omuro, Yasushi
Machida, Nozomu
Nishina, Tomohiro
Koue, Toshiko
Tsujimoto, Mika
Maeda, Kaijiro
Satoh, Taroh
Funding for this research was provided by:
Eli Lilly
Article History
Received: 11 January 2018
Accepted: 9 February 2018
First Online: 5 March 2018
Compliance with ethical standards
:
: Eli Lilly and Company was involved in the study design, data collection, data analysis, and preparation of the manuscript.
: KY and NM have received grants and personal fees from Eli Lilly and Company. FN has received grants from Taiho Pharmaceutical, Merck Serono, Zeria Pharmaceutical, Yakult, OncoTherapy Science, J-Pharma, Eli Lilly Japan K.K., Janssen Pharmaceutical, Bayer Yakuhin, Kyowa Hakko Kirin, Shionogi, Daiichi Sankyo, Takeda, Chugai Pharmaceutical, GlaxoSmithKline, Nippon Kayaku, Bristol-Myers Squibb, Mochida Pharmaceutical, Astellas Pharma, Ono Pharmaceutical, Sanofi S.A., Novartis, Torii Pharmaceutical, MSD, Covance Inc., Baxalta Japan, Eisai, NanoCarrier, and NPO Japan Clinical Research Support Unit. YO and TN have received grants from Eli Lilly and Company. TK, MT, and KM are employees of and own shares in Eli Lilly and Company. TS has received grants or personal fees from Yakult Honsha, Chugai Pharmaceutical, Ono Pharmaceutical, Eli Lilly and Company, Merck-Serono, Bristol-Myers Squibb, Takeda Pharmaceutical, Taiho Pharmaceutical, and Takara Bio. KF has no potential conflicts of interest to declare.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.